AIM ImmunoTech Inc is trading 5.5% down at $0.38 in pre-market, continuing a sharp downward trend following an 85% plunge on June 9.
- The selloff was triggered by the announcement of a $2.65 million at-market equity financing priced at $0.5189 per share.
- This financing move has significantly diluted existing shareholders, leading to intense selling pressure and ongoing market concerns regarding the capital raise.